Patients with chronic kidney disease (CKD) have a high burden of coronary artery calcification (CAC) and cardiovascular risk. GDF-15 is a stress-responsive biomarker linked to kidney dysfunction and adverse cardiovascular outcomes, but its relationship with CAC across CKD stages is incompletely characterized. We evaluated associations of GDF-15 with severe CAC and major adverse cardiovascular events (MACE). In this prospective observational study, 128 patients with CKD and no previous cardiovascular disease had baseline GDF-15, dp-ucMGP, high-sensitivity cardiac troponin I, and NT-proBNP measured; CAC was quantified by computed tomography in 127. Severe CAC was defined as Agatston score ≥ 400. Mean serum GDF-15 was 4.5 ± 3.4 ng/mL. GDF-15 discriminated severe CAC (AUC 0.728; 95% CI 0.642–0.804; p < 0.001). Each doubling of GDF-15 was associated with higher odds of severe CAC after adjustment for eGFR, diabetes, LDL cholesterol, and phosphate (OR 2.105; 95% CI 1.045–4.240; p = 0.037), but this association was attenuated after adding high-sensitivity troponin I (p = 0.086). During 19 months, nine MACE occurred; each doubling of GDF-15 was associated with higher MACE risk (HR 2.679; 95% CI 1.278–5.625; p = 0.009). Higher GDF-15 was associated with severe CAC and cardiovascular events, supporting further evaluation in CKD.
No takes yet. Share an insight, caveat, or question.
Kislikova et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: